@article{a498f1ee6e214549bd6c5bb10932fbfc,
title = "Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy",
abstract = "As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Manufacturing Practice (GMP)–compliant closed and automated systems to ensure reproducibility and to meet the increased demand for patients with cancer. In this review, we describe current CAR T cell clinical manufacturing models and discuss emerging technologic advances that embrace scaling and production optimization. We summarize measures being used to shorten CAR T cell manufacturing times and highlight regulatory challenges to scaling production for clinical use.",
author = "Mohamed Abou-El-Enein and Magdi Elsallab and Feldman, {Steven A.} and Fesnak, {Andrew D.} and Heslop, {Helen E.} and Peter Marks and Till, {Brian G.} and Gerhard Bauer and Barbara Savoldo",
note = "Funding Information: The authors thank David F. Stroncek (NIH) for his helpful comments on an earlier draft of the manuscript. They thank Catherine Gillespie (Baylor College of Medicine, Houston, TX) for her assistance in editing the manuscript. H.E. Heslop is supported by the NCI (P50CA126752), the Leukemia & Lymphoma Society, and a Stand Up To Cancer Dream Team Research Grant (grant number: SU2C-AACR-DT-29–19). The indicated SU2C research grant is administered by the American Association for Cancer Research, the scientific partner of SU2C. Funding Information: S.A. Feldman reports a patent for US201461935833P issued to KITE Pharma, a patent for US20200254018A1 pending, and a patent for EP2828290B1 issued. H.E. Heslop reports grants and personal fees from Tessa Therapeutics, grants from Kuur Therapeutics, NCI, AACR-SU2C, Leukemia & Lymphoma Society, and NIH: National Heart, Lung, and Blood Institute, and personal fees from Kiadis during the conduct of the study, as well as other support from Marker Therapeutics and Allovir outside the submitted work. B.G. Till reports other support from Mustang Bio outside the submitted work, as well as a patent for U.S. patent #10,875,927 issued and with royalties paid from Mustang Bio. B. Savoldo reports grants and other support from Tessa Theraputics and grants from bluebirdbio, NIH, Bellicum, and Cell Medica outside the submitted work. No disclosures were reported by the other authors. Publisher Copyright: {\textcopyright}2021 American Association for Cancer Research.",
year = "2021",
month = sep,
day = "1",
doi = "10.1158/2643-3230.BCD-21-0084",
language = "English (US)",
volume = "2",
pages = "408--422",
journal = "Blood cancer discovery",
issn = "2643-3249",
publisher = "NLM (Medline)",
number = "5",
}